Application of MMP-7 and MMP-10 in assisting the diagnosis of malignant pleural effusion

Asian Pacific Journal of Cancer Prevention

Volumn 13, Issue 2, 2012, Pages 505-509

  Cheng, Daye ^a   Liang, Bin ^a   Li, Yun Hui ^b  

^a CHINA MEDICAL UNIVERSITY   (China)

^b No 202 Hospital of PLA   (China)

Author keywords

Cancer; Diagnosis; Matrix metalloproteinases; Pleural effusion

Indexed keywords

MATRILYSIN; MMP7 PROTEIN, HUMAN; STROMELYSIN 2; TUMOR MARKER;

ARTICLE; COMPARATIVE STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYMOLOGY; FEMALE; FOLLOW UP; HUMAN; MALE; METABOLISM; MIDDLE AGED; NEOPLASM; PLEURA EFFUSION; PROGNOSIS;

ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MATRIX METALLOPROTEINASE 10; MATRIX METALLOPROTEINASE 7; MIDDLE AGED; NEOPLASMS; PLEURAL EFFUSION, MALIGNANT; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84866444551     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: 10.7314/APJCP.2012.13.2.505     Document Type: Article

References (33)

1. Aung PP, Oue N, Mitani Y, et al (2006). Systematic search for gastric cancer-specific genes based on SAGE data: melanomainhibitory activity and matrix metalloproteinase-10 are novel prognostic factors in patients with gastric cancer. Oncogene, 25, 2546-57.
2. Beeghly-Fadiel A, Shu XO, Long J, et al (2009). Genetic polymorphisms in the MMP-7 gene and breast cancer survival. Int J Cancer, 124, 208-14.
3. Birkedal-Hansen B, Pavelic ZP, Gluckman JL, et al (2000). MMP and TIMP gene expression in head and neck squamous cell carcinomas and adjacent tissues. Oral Diseases, 6, 376-82.
4. Bodey B, Bodey B, Jr Siegel SE, et al (2001). Matrix metalloproteinases in neoplasm-induced extracellular matrix remodeling in breast carcinomas. Anticancer Research, 21, 2021-8.
5. Dekker A, Bupp PA (1976). Cytology of serous effusions: a comparative study of two slightly different preparative methods. Acta Cytologica, 20, 394-9.
6. Fenton KN, Richardson JD (1995). Diagnosis and management of malignant pleural effusions. Am J Surgery, 170, 69-74.
7. Fiorelli A, Vicidomini G, Di Domenico M, et al (2011). Vascular endothelial growth factor in pleural fluid for differential diagnosis of benign and malignant origin and its clinical applications. Interat Cardiovasc Thorac Surg, 12, 420-4.
8. Garcia-Pachon E, Padilla-Navas I, Dosda MD, et al (1997). Elevated level of carcinoembryonic antigen in nonmalignant pleural effusions. Chest, 111, 643-7.
9. Kerkela E, Ala-aho R, Lohi J, et al (2001). Differential patterns of stromelysin-2 (MMP-10) and MT1-MMP (MMP-14) expression in epithelial skin cancers. Br J Cancer, 84, 659-69.
10. Liu H, Zhang T, Li X, et al (2008). Predictive value of MMP-7 expression for response to chemotherapy and survival in patients with non-small cell lung cancer. Cancer Sci 99, 2185-92.
11. Mathew R, Khanna R, Kumar R, et al (2002). Stromelysin-2 overexpression in human esophageal squamous cell carcinoma: potential clinical implications. Cancer Detect Prev, 26, 222-8.
12. Miserocchi G (1997). Physiology and pathophysiology of pleural fluid turnover. Eur Respir J, 10, 219-25.
13. Monte SA, Ehya H, Lang WR (1987). Positive effusion cytology as the initial presentation of malignancy. Acta Cytol, 31, 448-52.
14. Nagase H, Woessner JF Jr (1999). Matrix metalloproteinases. J Biol Chem, 274, 21491-4.
15. Nelson AR, Fingleton B, Rothenberg ML, et al (2000). Matrix metalloproteinases: biologic activity and clinical implications. J Clin Oncol, 18, 1135-49.
16. Newell KJ, Witty JP, Rodgers WH, et al (1994). Expression and localization of matrix-degrading metalloproteinases during colorectal tumorigenesis. Molec Carcinogenesis, 10, 199-206.
17. Paganuzzi M, Onetto M, Marroni P, et al (2001). Diagnostic value of CYFRA 21-1 tumor marker and CEA in pleural effusion due to mesothelioma. Chest, 119, 1138-42.
18. Porcel JM, Vives M, Esquerda A, et al (2004). Use of a panel of tumor markers (carcinoembryonic antigen, cancer antigen 125, carbohydrate antigen 15-3, and cytokeratin 19 fragments) in pleural fluid for the differential diagnosis of benign and malignant effusions. Chest, 126, 1757-63.
19. Riantawan P, Sangsayan P, Bangpattanasiri K, et al (2000). Limited additive value of pleural fluid carcinoembryonic antigen level in malignant pleural effusion. Respiration, 67, 24-9.
20. Ries C, Petrides PE (1995). Cytokine regulation of matrix metalloproteinase activity and its regulatory dysfunction in disease. Biol Chem Hoppe-Seyler, 376, 345-55.
21. Rittgers RA, Loewenstein MS, Feinerman AE, et al (1978). Carcinoembryonic antigen levels in benign and malignant pleural effusions. Ann Intern Med, 88, 631-4.
22. Romero S, Fernandez C, Arriero JM, et al (1996). CEA, CA 15-3 and CYFRA 21-1 in serum and pleural fluid of patients with pleural effusions. Eur Respir J, 9, 17-23.
23. Safranek J, Pesta M, Holubec L, et al (2009). Expression of MMP-7, MMP-9, TIMP-1 and TIMP-2 mRNA in lung tissue of patients with non-small cell lung cancer (NSCLC) and benign pulmonary disease. Anticancer Research, 29, 2513-7.
24. Sahn SA (1988). State of the art. The pleura. Am Rev Respir Dis, 138, 184-234.
25. Seargent JM, Loadman PM, Martin SW, et al (2005). Expression of matrix metalloproteinase-10 in human bladder transitional cell carcinoma. Urology, 65, 815-20.
26. Shi M, Liu D, Duan H, et al (2010). Catecholamine up-regulates MMP-7 expression by activating AP-1 and STAT3 in gastric cancer. Molec Cancer, 9, 269.
27. Shiomi T, Okada Y (2003). MT1-MMP and MMP-7 in invasion and metastasis of human cancers. Cancer Metastasis Rev, 22, 145-52.
28. Sounni NE, Noel A (2005). Membrane type-matrix metalloproteinases and tumor progression. Biochimie, 87, 329-42.
29. Szarvas T, Jager T, Becker M, et al (2011). Validation of circulating MMP-7 level as an independent prognostic marker of poor survival in urinary bladder cancer. Pathol Oncol Res, 17, 325-32.
30. Van de Molengraft FJ, Vooijs GP (1989). Survival of patients with malignancy-associated effusions. Acta Cytol, 33, 911-6.
31. Wasenius VM, Hemmer S, Kettunen E, et al (2003). Hepatocyte growth factor receptor, matrix metalloproteinase-11, tissue inhibitor of metalloproteinase-1, and fibronectin are up-regulated in papillary thyroid carcinoma: a cDNA and tissue microarray study. Clin Cancer Res, 9, 68-75.
32. Wobbes T, Thomas CM, Segers MF, et al (1992). Evaluation of seven tumor markers (CA 50, CA 19-9, CA 19-9 TruQuant, CA 72-4, CA 195, carcinoembryonic antigen, and tissue polypeptide antigen) in the pretreatment sera of patients with gastric carcinoma. Cancer, 69, 2036-41.
33. Woessner JF Jr (1991). Matrix metalloproteinases and their inhibitors in connective tissue remodeling. FASEB J, 5, 2145-54.